Please assess the completion status of the following clinical trial:

Trial Title: Danlou Tablets to Prevent Left Ventricular Remodeling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute myocardial infarction~* successfully underwent revascularization~Exclusion Criteria:~* previous myocardial infarction within 30 days~* malignant arrhythmia~* congenital heart disease~* cardiac shock~* documented or suspected history of heart failure or depressed LV ejection fraction \<15%~* planned coronary artery bypass grafting~* a life expectancy of \<1 year~* hepatic impairment~* glomerular filtration rate ≤30 mL/min per 1.73 m2~* autoimmune or connective tissue disease~* chronic substance abuse or psychiatric illness~* unable to complete 3 month clinical follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Danlou Tablets (Type: EXPERIMENTAL): Danlou tablets (4.5 g oral dose taken once daily) for 90 days
- placebo (Type: PLACEBO_COMPARATOR): matching placebo for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).